Overview

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Bromides
Formoterol Fumarate
Glycopyrrolate
Tiotropium Bromide